Abstract Imatinib, nilotinib, dasatinib, bosutinib, ponatinib, and asciminib are FDA-approved
tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML), each of which has a …

Introduction Imatinib has led to a phenomenal progress in the treatment of GIST. A rare and
lesser-known side effect of imatinib is pneumonitis, an uncommon multicausal interstitial …

Introduction: Imatinib has led to a phenomenal progress in the treatment of GIST. A rare and
lesser-known side effect of imatinib is pneumonitis, an uncommon multicausal interstitial …